FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004653259> ?p ?o ?g. }

• W2004653259 abstract "Abstract Background Injecting drug users (IDUs) in Taiwan contributed significantly to an HIV/AIDS epidemic in 2005. In addition, studies that identified risk factors of HCV/HIV co-infection among IDUs were sparse. This study aimed to identify risk factors of HCV/HIV co-infection and HCV mono-infection, as compared with seronegativity, among injecting drug users (IDUs) at a large methadone maintenance treatment program (MMTP) in Taipei, Taiwan. Methods Data from enrollment interviews and HCV and HIV testing completed by IDUs upon admission to the Taipei City Hospital MMTP from 2006–2010 were included in this cross-sectional analysis. HCV and HIV testing was repeated among re-enrollees whose HCV or HIV test results were negative at the preceding enrollment. Backward stepwise multinomial logistic regression was used to identify risk factors associated with HCV/HIV co-infection and HCV mono-infection. Results Of the 1,447 IDUs enrolled, the prevalences of HCV/HIV co-infection, HCV mono-infection, and HIV mono-infection were 13.1%, 78.0%, and 0.4%, respectively. In backward stepwise multinomial regression analysis, after controlling for potential confounders, syringe sharing in the 6 months before MMTP enrollment was significantly positively associated with HCV/HIV co-infection (adjusted odds ratio [AOR]=27.72, 95% confidence interval [CI] 13.30–57.76). Incarceration was also significantly positively associated with HCV/HIV co-infection (AOR=2.01, 95% CI 1.71–2.37) and HCV mono-infection (AOR=1.77, 95% CI 1.52–2.06), whereas smoking amphetamine in the 6 months before MMTP enrollment was significantly inversely associated with HCV/HIV co-infection (AOR=0.44, 95% CI 0.25–0.76) and HCV mono-infection (AOR=0.49, 95% CI 0.32–0.75). HCV seroincidence was 45.25/100 person-years at risk (PYAR; 95% CI 24.74–75.92/100 PYAR) and HIV seroincidence was 0.53/100 PYAR (95% CI 0.06–1.91/100 PYAR) among re-enrolled IDUs who were HCV- or HIV-negative at the preceding enrollment. Conclusions IDUs enrolled in Taipei MMTPs had very high prevalences of HCV/HIV co-infection and HCV mono-infection. Interventions such as expansion of syringe exchange programs and education regarding HCV/HIV prevention should be implemented for this high-risk group of drug users." @default.
• W2004653259 created "2016-06-24" @default.
• W2004653259 creator A5000569287 @default.
• W2004653259 creator A5017574957 @default.
• W2004653259 creator A5020928976 @default.
• W2004653259 creator A5024628055 @default.
• W2004653259 creator A5028075914 @default.
• W2004653259 creator A5054485583 @default.
• W2004653259 creator A5075001775 @default.
• W2004653259 date "2012-12-01" @default.
• W2004653259 modified "2023-09-26" @default.
• W2004653259 title "Prevalences and associated risk factors of HCV/HIV co-infection and HCV mono-infection among injecting drug users in a methadone maintenance treatment program in Taipei, Taiwan" @default.
• W2004653259 cites W1612443964 @default.
• W2004653259 cites W1963605590 @default.
• W2004653259 cites W1975184667 @default.
• W2004653259 cites W1976999181 @default.
• W2004653259 cites W1991140122 @default.
• W2004653259 cites W1998263952 @default.
• W2004653259 cites W2006020770 @default.
• W2004653259 cites W2019531133 @default.
• W2004653259 cites W2020292063 @default.
• W2004653259 cites W2031743478 @default.
• W2004653259 cites W2031791934 @default.
• W2004653259 cites W2062095485 @default.
• W2004653259 cites W206696804 @default.
• W2004653259 cites W2078203253 @default.
• W2004653259 cites W2079926718 @default.
• W2004653259 cites W2102027938 @default.
• W2004653259 cites W2103485728 @default.
• W2004653259 cites W2104563699 @default.
• W2004653259 cites W2120151546 @default.
• W2004653259 cites W2125196050 @default.
• W2004653259 cites W2127180629 @default.
• W2004653259 cites W2130917718 @default.
• W2004653259 cites W2133039181 @default.
• W2004653259 cites W2142344908 @default.
• W2004653259 cites W2156745854 @default.
• W2004653259 cites W2169085525 @default.
• W2004653259 cites W4214820698 @default.
• W2004653259 cites W83931366 @default.
• W2004653259 doi "https://doi.org/10.1186/1471-2458-12-1066" @default.
• W2004653259 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3534443" @default.
• W2004653259 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23227904" @default.
• W2004653259 hasPublicationYear "2012" @default.
• W2004653259 type Work @default.
• W2004653259 sameAs 2004653259 @default.
• W2004653259 citedByCount "25" @default.
• W2004653259 countsByYear W20046532592013 @default.
• W2004653259 countsByYear W20046532592014 @default.
• W2004653259 countsByYear W20046532592015 @default.
• W2004653259 countsByYear W20046532592016 @default.
• W2004653259 countsByYear W20046532592017 @default.
• W2004653259 countsByYear W20046532592018 @default.
• W2004653259 countsByYear W20046532592019 @default.
• W2004653259 countsByYear W20046532592020 @default.
• W2004653259 countsByYear W20046532592021 @default.
• W2004653259 countsByYear W20046532592023 @default.
• W2004653259 crossrefType "journal-article" @default.
• W2004653259 hasAuthorship W2004653259A5000569287 @default.
• W2004653259 hasAuthorship W2004653259A5017574957 @default.
• W2004653259 hasAuthorship W2004653259A5020928976 @default.
• W2004653259 hasAuthorship W2004653259A5024628055 @default.
• W2004653259 hasAuthorship W2004653259A5028075914 @default.
• W2004653259 hasAuthorship W2004653259A5054485583 @default.
• W2004653259 hasAuthorship W2004653259A5075001775 @default.
• W2004653259 hasBestOaLocation W20046532591 @default.
• W2004653259 hasConcept C118552586 @default.
• W2004653259 hasConcept C126322002 @default.
• W2004653259 hasConcept C156957248 @default.
• W2004653259 hasConcept C2778767360 @default.
• W2004653259 hasConcept C2778903061 @default.
• W2004653259 hasConcept C44249647 @default.
• W2004653259 hasConcept C71924100 @default.
• W2004653259 hasConceptScore W2004653259C118552586 @default.
• W2004653259 hasConceptScore W2004653259C126322002 @default.
• W2004653259 hasConceptScore W2004653259C156957248 @default.
• W2004653259 hasConceptScore W2004653259C2778767360 @default.
• W2004653259 hasConceptScore W2004653259C2778903061 @default.
• W2004653259 hasConceptScore W2004653259C44249647 @default.
• W2004653259 hasConceptScore W2004653259C71924100 @default.
• W2004653259 hasIssue "1" @default.
• W2004653259 hasLocation W20046532591 @default.
• W2004653259 hasLocation W20046532592 @default.
• W2004653259 hasLocation W20046532593 @default.
• W2004653259 hasLocation W20046532594 @default.
• W2004653259 hasOpenAccess W2004653259 @default.
• W2004653259 hasPrimaryLocation W20046532591 @default.
• W2004653259 hasRelatedWork W1843463370 @default.
• W2004653259 hasRelatedWork W1982619745 @default.
• W2004653259 hasRelatedWork W2002325000 @default.
• W2004653259 hasRelatedWork W2018589250 @default.
• W2004653259 hasRelatedWork W2114056959 @default.
• W2004653259 hasRelatedWork W2205814949 @default.
• W2004653259 hasRelatedWork W2417545465 @default.
• W2004653259 hasRelatedWork W2996661745 @default.
• W2004653259 hasRelatedWork W2999586795 @default.
• W2004653259 hasRelatedWork W4225673987 @default.
• W2004653259 hasVolume "12" @default.
• W2004653259 isParatext "false" @default.
• W2004653259 isRetracted "false" @default.

• next